Up next

Biotech Briefs: Enveda, Basecamp Research, Lisata & More 

The latest from small and Emerging Pharma companies featuring Enveda, Basecamp Research, Lisata Therapeutics, Marea Therapeutics and Travere Therapeutics. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Enveda Raises $311 M To Support Small-Molecule Drug Candidates 
* Basecamp Raises $140 M To Support In Vivo Cell Therapy Candidate 
* Lisata Therapeutics Acquires Marea Therapeutics 
* Travere Therapeutics Appoints New CEO 

Enveda Raises $311 M To Support Small-Molecule Drug Candidates  
Enveda, a Boulder, Colorado-based clinical-stage bio/pharmaceutical company with a proprietary AI platform based on natural products, has raised $311 million in Series E financing. This latest round brings the company’s total capital raised since inception to more than $845 million. 

Enveda’s PRISM is the company’s AI-native platform for identifying biologically active molecules found in nature, and the company will use the proceeds to advance three ongoing clinical-stage medicines into later-phase development that were developed using the PRISM platform.  

These medicines include ENV-294, a once-daily treatment for eczema and asthma currently in Phase II development, and ENV-308, a treatment for weight loss and metabolic health after stopping glucagon-like peptide-1 (GLP-1) medicines, into later-stage trials and additional indications, with new trials expected to begin in the coming months (as reported on September 23, 2026). Additionally, the proceeds will be used to advance ENV-6946, an oral treatment for inflammatory bowel disease currently in Phase I, through mid-phase trials as well as to bring additional medicines into clinical trials, including for other inflammatory and metabolic conditions and to continue scaling PRISM and the automated laboratory that feeds it.  

Source: Enveda 

Basecamp Raises $140 M To Support In Vivo Cell Therapy Candidate  
Basecamp Research, a London-based bio/pharmaceutical company focused on AI-designed in vivo cell therapies, has raised $140 million in Series C financing to support its development of in vivo cell therapies. Basecamp Research is applying EDEN, its biological foundation model, to in vivo cell therapy – reprogramming a patient’s cells inside the body. By engineering cells inside the body, the in vivo approach aims to eliminate the complex external manufacturing, hospital conditioning, and costs associated with traditional cell therapies. 

Source: Basecamp Research 

Lisata Therapeutics Acquires Marea Therapeutics 
Lisata Therapeutics, a Basking Ridge, New Jersey-based clinical-stage bio/pharmaceutical company, has acquired Marea Therapeutics, a South San Francisco, California-based clinical-stage bio/pharmaceutical company focused on cardioendocrine diseases, which are diseases borne from cardiovascular and endocrine systems. 

Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG), a disease characterized by very high fasting triglyceride levels, currently in Phase IIb and MAR002 for the treatment of acromegaly, a disease that causes organs to grow larger due to the body overproducing growth hormones, which is advancing to a Phase II study. 

The acquisition of Marea was structured as a stock-for-stock transaction to which all of Marea’s outstanding equity interests were exchanged based on a fixed exchange ratio for a combination of 1,793,129 shares of Lisata common stock and 211,365.213 shares of Series C non-voting convertible preferred stock. 

Concurrently with the acquisition of Marea, Lisata entered into a definitive purchase agreement for a private placement financing with life sciences investors and other institutional investors to raise $225 million. 

Source: Lisata Therapeutics 

Travere Therapeutics Appoints New CEO 
Travere Therapeutics, a San Diego, California-based bio/pharmaceutical company focused on rare diseases, has announced that Bradley L. Campbell, former President and Chief Executive Officer (CEO) of Amicus Therapeutic, and a wholly owned subsidiary of BioMarin Pharmaceutical, has been appointed President and CEO, effective December 1, 2026. He succeeds Eric Dube, Ph.D., who is stepping down as President and CEO to focus on his health and family. Dr. Dube will continue to serve as President and CEO until that date and will remain employed by the company as executive advisor through February 15, 2027, to support an orderly transition. 

Campbell brings more than 25 years of bio/pharmaceutical experience, much of it focused on developing medicines for rare diseases. Over nearly 20 years at Amicus, he held roles of increasing responsibility before becoming CEO in 2022. Previously, he held various commercial and business development roles at Genzyme and Bristol-Myers Squibb. Campbell currently serves on boards and advisory bodies, including the Advisory Board of the Duke-Margolis Institute for Health Policy. 

Source: Travere Therapeutics